Drugs / OMO-103
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07089940 | Jan 2026 → Dec 2027 expected | pancreatic ductal adenocarcinoma | OHSU Knight Cancer Institute | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06059001 | Aug 2023 → May 2026 overdue | malignant pancreatic neoplasm | Peptomyc S.L. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04808362 | Apr 2021 → Dec 2022 | malignant pancreatic neoplasm | Peptomyc S.L. | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT06650514 | Dec 2024 → Jun 2026 overdue | pediatric osteosarcoma | Vall d'Hebron Institute of Oncology | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2024-12-09 | Peptomyc S.L. | Regulatory Peptomyc announces Research IND Approval for Innovative Window of Opportunity Trial in Collaboration with OHSU Knight Cancer Institute, Portland, Oregon, USA, in PDAC patients peptomyc.com ↗
Peptomyc is pleased to announce the approval of a Research Investigational New Drug (IND) application for a groundbreaking Window of Opportunity trial in collaboration with Oregon Health & Science University (OHSU) Knight Cancer Institute and Brenden-Colson Center for Pancreatic Care (BCCPC). |
| 2024-02-06 | Peptomyc S.L. | Results Published today in Nature Medicine: Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial peptomyc.com ↗
Peptomyc is proud to announce that the results of the MYCure clinical trial have just been published in Nature Medicine (https://www.nature.com/articles/s41591-024-02805-1), demonstrating the unique potential of our lead first-in-class MYC inhibitor, OMO-103, to treat multiple oncological indications. |
| 2023-07-27 | Peptomyc S.L. | Regulatory Peptomyc announces the approval of its Phase 1b trial testing OMO-103 in combination with standard of care in PDAC patients peptomyc.com ↗ |
| 2022-11-01 | Peptomyc S.L. | Results Results from phase I clinical trial of the first drug to successfully inhibit the MYC protein, which drives many common cancers peptomyc.com ↗
Researchers have found that a drug that targets the key, cancer-causing gene, MYC, has for the first time been able to inhibit the function of the gene in a phase I clinical trial. |
| 2022-10-28 | Peptomyc S.L. | Results Omomyc as the first MYC-targeted therapy to successfully complete a phase I clinical trial peptomyc.com ↗
Results of the CT scans of the 17 evaluable patients showed that 8 had stable disease, with the treatment having halted tumor growth. |
| 2022-10-25 | Peptomyc S.L. | Results EORTC-NCI-AACR (ENA) Symposium 2022 in Barcelona peptomyc.com ↗
MYC inhibition by OMO-103 triggers an anti-tumor immune response in NSCLC preclinical models and modulates cytokine/chemokine profiles of Phase I patients. |
| 2021-03-16 | Peptomyc S.L. | Regulatory Green light by the AEMPS to start clinical trials with OMO-103 peptomyc.com ↗
Peptomyc is very proud to announce that today the company has reached another major milestone obtaining the approval from the Spanish authorities (AEMPS) to initiate the First in Human Phase I/II trial with its first compound OMO-103 in patients with advanced solid tumors. |
| 2020-12-21 | Peptomyc S.L. | Regulatory Peptomyc steps forward as a Clinical Stage Biotech company peptomyc.com ↗
Peptomyc S.L., a biotech company specialized in the development of protein and peptide therapeutics for cancer treatment, announces that it has officially transitioned from pre-clinical to Clinical Stage, having filed its first Clinical Trial Application in Europe. |
All press releases naming this drug 14 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMO-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06650514 ↗ |
| Action | Inhibit | “OMO-103 is a MYC inhibitor consisting of a 91-amino acid miniprotein.” PMID 38321218 ↗ Feb 2024 |
| Modality | Protein / enzyme biologic | “OMO-103 is a MYC inhibitor consisting of a 91-amino acid miniprotein.” PMID 38321218 ↗ Feb 2024 |
| Route | Intravenous | “OMO-103 will be administered intravenously as 30 min infusion once weekly” NCT04808362 ↗ |
| Target | MYC | “OMO-103 is a MYC inhibitor consisting of a 91-amino acid miniprotein.” PMID 38321218 ↗ Feb 2024 |